Last reviewed · How we verify
Dronabinol 30 mg
At a glance
| Generic name | Dronabinol 30 mg |
|---|---|
| Sponsor | INSYS Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (PHASE1)
- Dronabinol as an Adjunct for Reducing Pain (PHASE2)
- Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital (PHASE2)
- Effect of Cannabis on Cigarette Use Behavior (PHASE1)
- Improving Pain Disability With the Use of Oral Cannabinoids (NA)
- Effects of Pregnancy-associated Hormones on THC Metabolism in Women (PHASE4)
- Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (PHASE3)
- Effect of Cannabis on E-Cigarette Use Behavior (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dronabinol 30 mg CI brief — competitive landscape report
- Dronabinol 30 mg updates RSS · CI watch RSS
- INSYS Therapeutics Inc portfolio CI